



Home Office

2 Marsham Street
London
SW1P 4DF
www.gov.uk/home-office
FOIRequests@homeoffice.gov.uk

Jamie Halliday
[request-1449942-63321062@whatdotheyknow.com](#)

11 June 2026

Dear Jamie Halliday

Freedom of Information Request: FOI2026/06975

Thank you for your email of 26 May 2026, which we have included as Annex A. Your request has been handled as a request for information under the Freedom of Information Act 2000 (FOIA).

The Home Office does not hold the information which you have requested. The legislation governing cannabis-based products for medicinal use (CBPMs) does not impose THC (Delta-9-tetrahydrocannabinol) limits. Considerations around prescribing practices, dosages and routes of administration in relation to CBPMs sit outside of the remit of the Home Office and are the responsibility of the Department for Health and Social Care as well as regulators and professional bodies in the health sector.

If you are dissatisfied with this response you may request an independent internal review of our handling of your request by submitting a complaint within two months to foirequests@homeoffice.gov.uk, quoting reference **FOI2026/06975**. If you ask for an internal review, it would be helpful if you could say why you are dissatisfied with the response.

As part of any internal review the Department's handling of your information request would be reassessed by staff who were not involved in providing you with this response. If you were to remain dissatisfied after an internal review, you would have a right of complaint to the Information Commissioner as established by section 50 of the FOIA.

A link to the Home Office Information Rights Privacy Notice can be found in the following link. This explains how we process your personal information: <https://www.gov.uk/government/publications/information-rights-privacy-notice>

Yours sincerely

Public Safety Group

ANNEX A

Please treat this as a request for information under the Freedom of Information Act 2000.

This request concerns cannabis-based products for medicinal use (CBPMs), particularly dried cannabis flower prescribed in private healthcare settings.

I am seeking recorded information about whether any national, regulatory, clinical, inspection, safety, licensing or policy guidance exists in relation to maximum THC percentage limits for prescribed CBPM flower.

Please provide the following information.

1. Recorded guidance on THC percentage limits

Please provide any recorded guidance, policy, inspection guidance, regulatory guidance, internal briefing, position statement or other recorded information held by your organisation which refers to:

a. maximum THC percentage limits for prescribed CBPM flower; b. THC percentage thresholds such as 20%, 22%, 25%, 26%, 28%, 30% or similar; c. whether prescribers or clinics should restrict patients to a maximum THC percentage; d. whether higher-THC CBPM flower requires additional clinical justification, approval, review, risk assessment or governance oversight.

2. Basis for any THC percentage cap or threshold

If your organisation holds information suggesting that THC percentage caps or thresholds are used, recommended, expected or considered good practice, please provide recorded information explaining:

a. the clinical, regulatory or evidential basis for those caps or thresholds; b. whether such caps are mandatory, advisory, discretionary, or left to prescriber judgement; c. whether any cap differs depending on diagnosis, age, psychiatric history, prior cannabis use, tolerance, treatment response, dose, route of administration, or risk of misuse/diversion.

3. Private clinic prescribing governance

Please provide recorded information held by your organisation about how private CBPM clinics are expected to justify, review, audit or document decisions involving higher-THC flower.

This includes any recorded information about:

- a. prescribing governance;
- b. multidisciplinary review;
- c. specialist sign-off;
- d. audit requirements;
- e. risk assessments;
- f. patient-specific clinical rationale;
- g. situations where a clinic restricts product strength or THC percentage.

4. No information held

If your organisation does not hold any recorded information setting, recommending, endorsing or discussing a maximum THC percentage limit for prescribed CBPM flower,

please confirm this explicitly.

For clarity, I am not requesting patient-identifiable information, individual prescribing records, or information about any specific patient.

Please provide the information electronically.